Deals Of The Week: Astellas/CVT, GSK/NeuroSearch, Deerfield/NitroMed ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings
In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
Deerfield To NitroMed: Not So Fast, Not So Cheap
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.